<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACC Adv</journal-id><journal-id journal-id-type="iso-abbrev">JACC Adv</journal-id><journal-title-group><journal-title>JACC: Advances</journal-title></journal-title-group><issn pub-type="epub">2772-963X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40286372</article-id><article-id pub-id-type="pmc">PMC12103078</article-id><article-id pub-id-type="pii">S2772-963X(25)00133-4</article-id><article-id pub-id-type="doi">10.1016/j.jacadv.2025.101716</article-id><article-id pub-id-type="publisher-id">101716</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Healthcare Expenditure on Atrial&#x000a0;Fibrillation in the United States</article-title><subtitle>The Medical Expenditure Panel Survey 2016 to 2021</subtitle></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>See</surname><given-names>Claudia</given-names></name><degrees>MD, MBA</degrees><email>claudia.see@ucsf.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Grubman</surname><given-names>Scott</given-names></name><degrees>MD, MHS</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Shah</surname><given-names>Nisarg</given-names></name><degrees>BS</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Hu</surname><given-names>Jiun-Ruey</given-names></name><degrees>MD, MPH</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Nanna</surname><given-names>Michael</given-names></name><degrees>MD, MHS</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Freeman</surname><given-names>James V.</given-names></name><degrees>MD, MPH, MS</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Murugiah</surname><given-names>Karthik</given-names></name><degrees>MBBS, MHS</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><aff id="aff1"><label>a</label>Division of General Internal Medicine, University of California, San Francisco, California, USA</aff><aff id="aff2"><label>b</label>Division of General Internal Medicine, The Mount Sinai Hospital, New York, New York, USA</aff><aff id="aff3"><label>c</label>Yale School of Medicine, New Haven, Connecticut, USA</aff><aff id="aff4"><label>d</label>Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA</aff><aff id="aff5"><label>e</label>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA</aff><aff id="aff6"><label>f</label>Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Address for correspondence:</bold> Dr Claudia See, UCSF Parnassus Medical Center, 505 Parnassus Avenue, San Francisco, California 94143, USA. <email>claudia.see@ucsf.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>4</month><year>2025</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>101716</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Atrial fibrillation (AF) prevalence is increasing, and management is evolving. This study builds on prior studies focusing on AF healthcare expenditures.</p></sec><sec><title>Objectives</title><p>The purpose of this study was to provide a contemporary nationally representative assessment of AF and atrial flutter expenditures in the United States.</p></sec><sec><title>Methods</title><p>Using Medical Expenditure Panel Survey 2016 to 2021 data, we identified individuals with AF or atrial flutter using International Classification of Disease-10 codes and reported total and categorized expenditures. Using 2-part and gamma regression models, respectively, we estimated the incremental AF expenditures for the entire population and for individuals with common coexisting comorbidities. Among AF individuals, we identified characteristics associated with higher expenditures.</p></sec><sec><title>Results</title><p>Of a weighted surveyed population of 248,067,064 adults, 3,564,763 (1.4%) had AF, with a mean age 71.9&#x000a0;&#x000b1;&#x000a0;10.6&#x000a0;years, and 45.7% were female. The mean unadjusted annual total healthcare expenditure was $25,451&#x000a0;&#x000b1;&#x000a0;$1,100 ($9,254&#x000a0;&#x000b1;&#x000a0;$82 without AF). Highest spending categories were inpatient visits ($7,975&#x000a0;&#x000b1;&#x000a0;$733) and prescriptions ($6,505&#x000a0;&#x000b1;&#x000a0;$372). AF expenditures increased over the study period by 11.1%. After adjustment, the incremental annual expenditure attributable to AF was $6,185 per person. Incremental AF expenditures were highest for those with cancer at $12,052 ($4,476-$19,627), while AF did not significantly increase expenditures in heart failure at $30 (&#x02212;$7,660 to $7,716). Cancer, modified Charlson Comorbidity Index of 1 or&#x000a0;&#x02265;2, chronic kidney disease, type 2 diabetes mellitus, chronic obstructive pulmonary disease, atherosclerotic cardiovascular disease, poor income level, bachelor&#x02019;s degree, and later survey year were associated with higher expenditures.</p></sec><sec><title>Conclusions</title><p>AF is associated with substantial and increasing healthcare expenditures. With changing screening and management, expenditures need periodic reassessments.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Central Illustration</title><fig id="undfig1" position="anchor"><graphic xlink:href="ga1"/></fig></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>atrial fibrillation</kwd><kwd>comorbidities</kwd><kwd>expenditures</kwd><kwd>socioeconomic status</kwd></kwd-group></article-meta><def-list><title>Abbreviations and Acronyms</title><def-item><term id="kwrd0020">AF</term><def><p>atrial fibrillation</p></def></def-item><def-item><term id="kwrd0020a">AHRQ</term><def><p>Agency of Healthcare Research and Quality</p></def></def-item><def-item><term id="kwrd0020b">ASCVD</term><def><p>atherosclerotic cardiovascular disease</p></def></def-item><def-item><term id="kwrd0020c">CCI</term><def><p>Charlson Comorbidity Index</p></def></def-item><def-item><term id="kwrd0020d">CKD</term><def><p>chronic kidney disease</p></def></def-item><def-item><term id="kwrd0020e">COPD</term><def><p>chronic obstructive pulmonary disease</p></def></def-item><def-item><term id="kwrd0020f">DOAC</term><def><p>direct-acting oral anticoagulant</p></def></def-item><def-item><term id="kwrd0020g">FPL</term><def><p>federal poverty line</p></def></def-item><def-item><term id="kwrd0020h">HF</term><def><p>heart failure</p></def></def-item><def-item><term id="kwrd0020i">HTN</term><def><p>hypertension</p></def></def-item><def-item><term id="kwrd0020j">ICD</term><def><p>International Classification of Disease</p></def></def-item><def-item><term id="kwrd0020z">MEPS</term><def><p>Medical Expenditure Panel Survey</p></def></def-item><def-item><term id="kwrd0020v">T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item></def-list></front><body><p id="p0010">Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 and 6.1 million people in the U.S.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Over time, with an aging population and potentially increased detection due to improved and more widespread monitoring devices, the prevalence of AF has been rising, and the prevalence is estimated to be 12.1 million by 2030.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p><p id="p0015">AF is associated with significant morbidity, including hospitalizations and risk of cardiovascular and cerebrovascular events.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Given these characteristics, AF is associated with high healthcare expenditures.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> The management of AF has been evolving in recent times, with increased use of antiarrhythmics and procedures to maintain sinus rhythm as well as increased use of direct-acting oral anticoagulants (DOACs) and left atrial appendage occlusion for stroke prevention, which can affect overall expenditures. However, contemporary studies of U.S. national healthcare expenditures for AF care have been lacking. Furthermore, AF frequently co-exists with other important chronic comorbidities such as heart failure (HF), atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cancer, type 2 diabetes mellitus (T2DM), and hypertension (HTN), all of which may complicate their management.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> How expenditures of these conditions are influenced by co-existent AF has not been well evaluated.</p><p id="p0020">Accordingly, the aim of this study was to report current nationally representative healthcare expenditures and recent trends for individuals with AF (categorizing expenditures across medical service categories such as hospitalizations and prescriptions), estimate the incremental expenditures attributable to AF, and identify the characteristics of individuals with AF who experience higher expenditures.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Data sources</title><p id="p0025">The Medical Expenditure Panel Survey (MEPS) is an annual cross-sectional survey of U.S. families and individuals by the Agency of Healthcare Research and Quality (AHRQ). It is the largest all-payer nationally representative annual cross-sectional survey of medical expenditures of the U.S. civilian, noninstitutionalized population.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> MEPS collects data on demographic characteristics, health conditions, health status, use of medical services, charges and source of payments, access to care, satisfaction with care, health insurance coverage, income, and employment. Overall response rates in the years 2016 to 2021 were approximately 22% to 46%.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p><p id="p0030">The panel design of the survey includes 5 rounds of interviews covering 2 full calendar years. Every year, a new panel of about 15,000 sample households is selected. The set of households selected for each panel is a subsample of households participating in the previous year's National Health Interview Survey conducted by the National Center for Health Statistics.</p><p id="p0035">Data from the MEPS Household Component Full-Year Consolidated Data Files and Medical Conditions Files were pooled across the years 2016 to 2021 and then merged using 2 variables&#x02014;patient identifier variable &#x0201c;DUPERSID&#x0201d; and survey &#x0201c;Year.&#x0201d; The study was limited to 2016 and after because the International Classification of Disease (ICD)-9 codes used in MEPS data before 2016 were limited to three digits for confidentiality reasons and could not distinguish AF from other cardiac arrhythmias. For 2016 and 2017, the 2-digit panel number from the variable &#x0201c;PANEL&#x0201d; was added in front of all DUPERSIDs as per the recommendation of AHRQ<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> to be consistent across all survey years. Families and individuals were assigned weights based on demographic proportions in the overall U.S. population.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> The National Health Interview Survey sample design underwent several changes between 2016 and 2021, such as discontinuation of oversampling of Asian, Black, and Hispanic minority groups<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> in favor of oversampling of Veterans and middle-sized states.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> To compensate for low response rates during the COVID-19 pandemic, MEPS extended the duration of its survey panels by 1&#x000a0;year.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p><p id="p0040">As all data and materials are de-identified and publicly available, this study was exempt from institutional review board approval by Yale University.</p></sec><sec id="sec1.2"><title>Study population</title><p id="p0045">The study population included all adults aged 18&#x000a0;years or older. AF and atrial flutter were identified using the ICD-10 code &#x0201c;I48.&#x0201d; Similarly, the comorbidities ASCVD, HF, HTN, CKD, COPD, cancer, and T2DM were identified using appropriate ICD-10 codes (<xref rid="appsec1" ref-type="sec">Supplemental Table&#x000a0;1</xref>). The weighted population size was estimated as the average annual population size for the pooled period, based on the recommendation from AHRQ on pooling.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></p></sec><sec id="sec1.3"><title>Variables and Preprocessing</title><p id="p0050">Age was categorized into 18 to 44, 45 to 64, 65 to 84, and&#x000a0;&#x02265;85&#x000a0;years old, and sex as male or female. Race/ethnicity was categorized as non-Hispanic White, Hispanic, non-Hispanic Black, and non-Hispanic Asian and other/mixed race. Marital status was categorized as married, never married, and divorced/widowed/separated. Insurance status was categorized as private, Medicare, other public, or uninsured. Education was categorized as no degree, general educational development or high school graduate, bachelor's degree, master's or doctorate degree, and other degrees. Individuals were classified as living in one of 4 census regions: Northeast, Midwest, South, or West.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Family income was categorized as poor (families with income less than or equal to the federal poverty line [FPL]), near-poor (100%-125% of the FPL), low income (125%-200% of the FPL), middle income (200%-400% of the FPL), and high income (&#x0003e;400% of the FPL) per the MEPS poverty status variable. In the multivariable models, survey year was treated as a continuous variable. The Stata &#x0201c;charlson&#x0201d; package was used to calculate the Charlson Comorbidity Index (CCI) score.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> A higher score represents more comorbid conditions.</p><p id="p0055">Total medical expenditure was defined as the sum of direct payments for care across 8 medical service categories: inpatient hospitalization stays, outpatient and office-based visits, prescription medication, emergency department visits, dental visits, home healthcare, and others (including dental and vision expenditures). Payments were combined across 10 payers such as private insurance, Medicare, Medicaid, Tricare, out-of-pocket, and other. All expenditures and incomes in our analyses were inflation adjusted to year 2021 using the Consumer Price Index. Home health expenditures were derived by summed home health agency and home health nonagency expenditure MEPS variables. Other expenditures were derived by summed dental, vision, and &#x0201c;other&#x0201d; expenditure MEPS variables.</p><p id="p0060">Demographic variable data reported as missing in the MEPS database (ie, cannot be computed, do not know, refused, and inapplicable) were excluded from the analysis. In addition, MEPS compensates for missing medical expenditure data through a weighted hot-deck imputation approach, which uses survey responses and weights to impute missing data, preserving sample sizes and reducing nonresponse bias.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p></sec><sec id="sec1.4"><title>Statistical methods</title><p id="p0065">Continuous variables were presented as both mean&#x000a0;&#x000b1;&#x000a0;SD and median (IQR). Categorical variables were presented as proportions. Continuous data were compared with the Wilcoxon rank-sum test (as they did not follow a normal distribution), and categorical data were compared with chi-squared tests. A 2-sided <italic>P</italic> value of&#x000a0;&#x0003c;0.05 was used for statistical significance. MEPS survey weights were applied using the &#x0201c;svy&#x0201d; function in Stata. Statistical analysis was conducted using Stata Statistical Software: Release 18 (Stata Corp.).</p></sec><sec id="sec1.5"><title>Modeling healthcare expenditure</title><p id="p0070">For expenditure data which are typically right-skewed,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> a 2-part model was used&#x02014;the first model is a logistic or probabilistic (probit) regression model which estimates the probability of zero vs positive expenditures, and the second model is conditional on having a positive annual healthcare expenditure, such as a generalized linear model with gamma distribution and a logarithmic-link function that estimates the average expenditure per capita.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref></p><p id="p0075">First, a 2-part regression model was created using the entire pooled population with and without AF to estimate incremental total healthcare expenditure attributable to AF. Covariates included in multivariable adjustment were AF, age, sex, race/ethnicity, survey year, CCI, poverty level, education status, marital status, geographic region, and insurance status. National estimates of AF expenditure were extrapolated by multiplying the incremental expenditure per person by the survey weighted number of individuals with AF in the U.S. in our study; second, incremental expenditures attributable to AF within subpopulations of individuals with 7 other common chronic comorbidities of ASCVD, HF, HTN, CKD, COPD, cancer, and T2DM were estimated by creating a single gamma regression model for each subpopulation and calculating the average marginal effect with 95% CIs. Gamma models were used instead of 2-part models because of the low prevalence of individuals with no expenditures within the comorbidity subpopulations. Covariates included in multivariable adjustment were AF, age, sex, race/ethnicity, survey year, modified CCI, individual comorbidities, poverty level, education status, marital status, geographic region, and insurance status. For these gamma regression models, a &#x0201c;modified&#x0201d; CCI was used by excluding the 7 comorbidities of ASCVD, HF, HTN, CKD, COPD, cancer, and T2DM from the CCI calculation,<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> resulting in 3 final score categories of 0, 1, and&#x000a0;&#x02265;2. This was done to enable inputting these comorbidities as separate covariates into the model to study their individual effects.</p><p id="p0080">Third, individual characteristics associated with increased total healthcare expenditures were determined by creating a gamma regression model only for individuals with AF and calculating ORs with 95%&#x000a0;CI. For this gamma regression model, the &#x0201c;modified&#x0201d; CCI covariate was also used.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Study population characteristics</title><p id="p0085">The average annual surveyed population was 22,911 U.S. adults aged&#x000a0;&#x02265;18&#x000a0;years. Of these, 98.6% had complete data (n&#x000a0;=&#x000a0;22,583), equivalent to a survey weighted population of 248,067,064 adults. Within this population with complete data, 1,902 survey respondents had AF, equivalent to a survey weighted population of 3,564,763 adults and an overall AF prevalence of 1.4%.</p><p id="p0090"><xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref> shows demographics, comorbidities, and total expenditures by category for the overall population and for those with and without AF.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Demographics, Comorbidities, and Annual Expenditures of Individuals With and Without AF From 2016 to 2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All</th><th>AF</th><th>Non-AF</th></tr></thead><tbody><tr><td>Average annual weighted population, N<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">248,067,064</td><td align="center">3,564,763</td><td align="center">244,502,302</td></tr><tr><td>Average annual sample size, n<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="center">22,583</td><td align="center">317</td><td align="center">22,266</td></tr><tr><td colspan="4">Age categories</td></tr><tr><td>&#x000a0;18-44&#x000a0;y</td><td align="center">45.8</td><td align="center">2.4</td><td align="center">46.4</td></tr><tr><td>&#x000a0;45-64&#x000a0;y</td><td align="center">33.1</td><td align="center">19.3</td><td align="center">33.3</td></tr><tr><td>&#x000a0;65-84&#x000a0;y</td><td align="center">18.8</td><td align="center">64.0</td><td align="center">18.2</td></tr><tr><td>&#x000a0;&#x02265;85&#x000a0;y</td><td align="center">2.3</td><td align="center">14.3</td><td align="center">2.2</td></tr><tr><td colspan="4">Sex</td></tr><tr><td>&#x000a0;Female</td><td align="center">51.7</td><td align="center">45.7</td><td align="center">51.8</td></tr><tr><td>&#x000a0;Male</td><td align="center">48.3</td><td align="center">54.3</td><td align="center">48.2</td></tr><tr><td colspan="4">Race</td></tr><tr><td>&#x000a0;Non-Hispanic White</td><td align="center">62.7</td><td align="center">89.0</td><td align="center">62.3</td></tr><tr><td>&#x000a0;Hispanic</td><td align="center">16.4</td><td align="center">3.3</td><td align="center">16.6</td></tr><tr><td>&#x000a0;Non-Hispanic Black</td><td align="center">11.9</td><td align="center">4.6</td><td align="center">12.0</td></tr><tr><td>&#x000a0;Non-Hispanic Asian and other/mixed race</td><td align="center">9.1</td><td align="center">3.2</td><td align="center">9.1</td></tr><tr><td colspan="4">Marital status (%)</td></tr><tr><td>&#x000a0;Married</td><td align="center">51.7</td><td align="center">59.7</td><td align="center">51.6</td></tr><tr><td>&#x000a0;Widowed/divorced/separated</td><td align="center">19.4</td><td align="center">34.5</td><td align="center">19.2</td></tr><tr><td>&#x000a0;Never married</td><td align="center">28.9</td><td align="center">5.9</td><td align="center">29.2</td></tr><tr><td colspan="4">Education level</td></tr><tr><td>&#x000a0;GED/High school diploma</td><td align="center">45.0</td><td align="center">50.7</td><td align="center">44.9</td></tr><tr><td>&#x000a0;Bachelor's degree</td><td align="center">20.9</td><td align="center">14.6</td><td align="center">21.0</td></tr><tr><td>&#x000a0;Master/Doctorate</td><td align="center">12.3</td><td align="center">19.4</td><td align="center">12.2</td></tr><tr><td>&#x000a0;Other degree</td><td align="center">10.1</td><td align="center">9.3</td><td align="center">10.1</td></tr><tr><td>&#x000a0;No degree</td><td align="center">11.8</td><td align="center">6.1</td><td align="center">11.9</td></tr><tr><td colspan="4">Census region</td></tr><tr><td>&#x000a0;Northeast</td><td align="center">17.5</td><td align="center">21.4</td><td align="center">17.4</td></tr><tr><td>&#x000a0;Midwest</td><td align="center">20.8</td><td align="center">25.5</td><td align="center">20.8</td></tr><tr><td>&#x000a0;South</td><td align="center">37.9</td><td align="center">37.3</td><td align="center">38.0</td></tr><tr><td>&#x000a0;West</td><td align="center">23.7</td><td align="center">15.9</td><td align="center">23.9</td></tr><tr><td colspan="4">Household income level</td></tr><tr><td>&#x000a0;Poor/Negative</td><td align="center">10.4</td><td align="center">7.5</td><td align="center">10.5</td></tr><tr><td>&#x000a0;Near poor</td><td align="center">3.7</td><td align="center">3.4</td><td align="center">3.7</td></tr><tr><td>&#x000a0;Low income</td><td align="center">11.9</td><td align="center">13.9</td><td align="center">11.9</td></tr><tr><td>&#x000a0;Middle income</td><td align="center">28.5</td><td align="center">28.0</td><td align="center">28.5</td></tr><tr><td>&#x000a0;High income</td><td align="center">45.4</td><td align="center">47.2</td><td align="center">45.4</td></tr><tr><td colspan="4">Insurance status</td></tr><tr><td>&#x000a0;Private</td><td align="center">58.7</td><td align="center">16.8</td><td align="center">59.3</td></tr><tr><td>&#x000a0;Medicare</td><td align="center">12.5</td><td align="center">78.2</td><td align="center">12.7</td></tr><tr><td>&#x000a0;Other public</td><td align="center">7.6</td><td align="center">4.3</td><td align="center">7.7</td></tr><tr><td>&#x000a0;Uninsured</td><td align="center">21.1</td><td align="center">0.7</td><td align="center">20.2</td></tr><tr><td colspan="4">CCI</td></tr><tr><td>&#x000a0;0</td><td align="center">83.4</td><td align="center">50.6</td><td align="center">83.9</td></tr><tr><td>&#x000a0;1</td><td align="center">11.0</td><td align="center">26.3</td><td align="center">10.8</td></tr><tr><td>&#x000a0;&#x02265;2</td><td align="center">5.6</td><td align="center">23.0</td><td align="center">5.3</td></tr><tr><td colspan="4">Comorbidities</td></tr><tr><td>&#x000a0;HTN</td><td align="center">32.8</td><td align="center">67.9</td><td align="center">32.1</td></tr><tr><td>&#x000a0;T2DM</td><td align="center">13.3</td><td align="center">22.2</td><td align="center">13.1</td></tr><tr><td>&#x000a0;ASCVD</td><td align="center">5.6</td><td align="center">34.7</td><td align="center">5.2</td></tr><tr><td>&#x000a0;Cancer</td><td align="center">3.5</td><td align="center">12.6</td><td align="center">3.4</td></tr><tr><td>&#x000a0;COPD</td><td align="center">2.3</td><td align="center">9.5</td><td align="center">2.2</td></tr><tr><td>&#x000a0;HF</td><td align="center">0.7</td><td align="center">7.0</td><td align="center">0.6</td></tr><tr><td>&#x000a0;CKD</td><td align="center">0.6</td><td align="center">2.1</td><td align="center">0.6</td></tr><tr><td colspan="4">Survey year</td></tr><tr><td>&#x000a0;2016</td><td align="center">16.4</td><td align="center">15.3</td><td align="center">16.4</td></tr><tr><td>&#x000a0;2017</td><td align="center">16.6</td><td align="center">14.4</td><td align="center">16.6</td></tr><tr><td>&#x000a0;2018</td><td align="center">16.7</td><td align="center">15.9</td><td align="center">16.7</td></tr><tr><td>&#x000a0;2019</td><td align="center">16.7</td><td align="center">18.2</td><td align="center">16.7</td></tr><tr><td>&#x000a0;2020</td><td align="center">16.8</td><td align="center">16.4</td><td align="center">16.8</td></tr><tr><td>&#x000a0;2021</td><td align="center">16.8</td><td align="center">19.8</td><td align="center">16.8</td></tr><tr><td colspan="4">Annual unadjusted expenditures<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td></tr><tr><td>&#x000a0;Total</td><td align="center">$7,392&#x000a0;&#x000b1;&#x000a0;$67</td><td align="center">$25,451&#x000a0;&#x000b1;&#x000a0;$1,100</td><td align="center">$7,129&#x000a0;&#x000b1;&#x000a0;$66</td></tr><tr><td>&#x000a0;Inpatient</td><td align="center">$1,598&#x000a0;&#x000b1;&#x000a0;$33</td><td align="center">$7,975&#x000a0;&#x000b1;&#x000a0;$733</td><td align="center">$1,506&#x000a0;&#x000b1;&#x000a0;$32</td></tr><tr><td>&#x000a0;Prescription</td><td align="center">$1,822&#x000a0;&#x000b1;&#x000a0;$34</td><td align="center">$6,505&#x000a0;&#x000b1;&#x000a0;$372</td><td align="center">$1,753&#x000a0;&#x000b1;&#x000a0;$34</td></tr><tr><td>&#x000a0;Office based</td><td align="center">$1,918&#x000a0;&#x000b1;&#x000a0;$24</td><td align="center">$4,716&#x000a0;&#x000b1;&#x000a0;$247</td><td align="center">$1,877&#x000a0;&#x000b1;&#x000a0;$24</td></tr><tr><td>&#x000a0;Outpatient</td><td align="center">$801&#x000a0;&#x000b1;&#x000a0;$19</td><td align="center">$2,867&#x000a0;&#x000b1;&#x000a0;$314</td><td align="center">$771&#x000a0;&#x000b1;&#x000a0;$19</td></tr><tr><td>&#x000a0;Home health<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td align="center">$372&#x000a0;&#x000b1;&#x000a0;$15</td><td align="center">$1,345&#x000a0;&#x000b1;&#x000a0;$138</td><td align="center">$357&#x000a0;&#x000b1;&#x000a0;$15</td></tr><tr><td>&#x000a0;ED</td><td align="center">$246&#x000a0;&#x000b1;&#x000a0;$4</td><td align="center">$715&#x000a0;&#x000b1;&#x000a0;$90</td><td align="center">$239&#x000a0;&#x000b1;&#x000a0;$4</td></tr><tr><td>&#x000a0;Other<xref rid="tbl1fnd" ref-type="table-fn">d</xref></td><td align="center">$637&#x000a0;&#x000b1;&#x000a0;$6</td><td align="center">$1,329&#x000a0;&#x000b1;&#x000a0;$66</td><td align="center">$626&#x000a0;&#x000b1;&#x000a0;$7</td></tr><tr><td colspan="4">Annual unadjusted expenditures<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td></tr><tr><td>&#x000a0;Total</td><td align="center">$1,696 ($304-$6,258)</td><td align="center">$13,570 ($6,859-$29,708)</td><td align="center">$1,616 ($292-$5,979)</td></tr><tr><td>&#x000a0;Inpatient</td><td align="center">$0 ($0-$0)</td><td align="center">$0 ($0-$5,684)</td><td align="center">$0 ($0-$0)</td></tr><tr><td>&#x000a0;Prescription</td><td align="center">$71 ($0-$698)</td><td align="center">$3,223 ($885-$6,626)</td><td align="center">$65 ($0-$649)</td></tr><tr><td>&#x000a0;Office based</td><td align="center">$444 ($40-$1,608)</td><td align="center">$2,416 ($1,018-$4,909)</td><td align="center">$430 ($0-$1,561)</td></tr><tr><td>&#x000a0;Outpatient</td><td align="center">$0 ($0-$0)</td><td align="center">$150 ($0-$1,856)</td><td align="center">$0 ($0-$0)</td></tr><tr><td>&#x000a0;Home health<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td align="center">$0 ($0-$0)</td><td align="center">$0 ($0-$0)</td><td align="center">$0 ($0-$0)</td></tr><tr><td>&#x000a0;ED</td><td align="center">$0 ($0-$0)</td><td align="center">$0 ($0-$443)</td><td align="center">$0 ($0-$0)</td></tr><tr><td>&#x000a0;Other<xref rid="tbl1fnd" ref-type="table-fn">d</xref></td><td align="center">$123 ($0-$559)</td><td align="center">$504 ($88-$1,595)</td><td align="center">$119 ($0-$550)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are %, mean&#x000a0;&#x000b1;&#x000a0;SD, or median (IQR). All variables had <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Average annual population sizes are calculated by dividing each total population over 2016 to 2021 by 6&#x000a0;years and rounding up to the nearest whole integer.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Expenditures are reported in inflation-adjusted 2021 U.S. dollars.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntpara0020">Home health expenditures are summed as home health agency and home health nonagency expenditure MEPS variables.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnd"><label>d</label><p id="ntpara0020a">Other expenditures are summed as dental, vision, and other expenditure MEPS variables.</p></fn></table-wrap-foot></table-wrap></p><p id="p0095">Among individuals with AF, the mean age was 71.9&#x000a0;&#x000b1;&#x000a0;10.6&#x000a0;years, 45.7% were female, and 89.0% were non-Hispanic White. The median CCI was 1 (IQR: 0-1). Among individuals without AF, the mean age was 47.5&#x000a0;&#x000b1;&#x000a0;18.2&#x000a0;years, 51.8% were female, and 62.3% were non-Hispanic White. The median CCI was 0 (IQR: 0-0) for individuals without AF. The top chronic comorbidities among individuals with AF (compared with individuals without AF) were HTN (prevalence of 67.9% in those with AF vs 32.1% among those without), T2DM (22.2% vs 13.1%), ASCVD (34.7% vs 5.2%), cancer (12.6% vs 3.4%), COPD (9.5% vs 2.2%), HF (7.0% vs 0.6%), and CKD (2.1% vs 0.6%) (all <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec id="sec2.2"><title>Healthcare expenditures with AF</title><p id="p0100">For individuals with AF, the average unadjusted annual total healthcare expenditure in terms of 2021 inflation-adjusted dollars was $25,451&#x000a0;&#x000b1;&#x000a0;$1,100 (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>) compared with $9,254&#x000a0;&#x000b1;&#x000a0;$82 for individuals without AF (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). For comparison, the average unadjusted annual total healthcare expenditures among individuals with other chronic diseases&#x02014;CKD, HF, cancer, ASCVD, COPD, T2DM, and HTN&#x02014;were $46,524&#x000a0;&#x000b1;&#x000a0;$3,129, $33,753&#x000a0;&#x000b1;&#x000a0;$2,026, $25,212&#x000a0;&#x000b1;&#x000a0;$998, $23,096&#x000a0;&#x000b1;&#x000a0;$530, $21,725&#x000a0;&#x000b1;&#x000a0;$675, $17,125&#x000a0;&#x000b1;&#x000a0;$337, and $13,622&#x000a0;&#x000b1;&#x000a0;$207, respectively. Median unadjusted annual total healthcare expenditure for individuals with AF was $13,570 ($6,859-$29,708), compared with&#x000a0;$1,616 ($292-$5,979) for individuals without AF (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).</p><p id="p0105">The highest average expenditures among service categories in AF were inpatient ($7,975&#x000a0;&#x000b1;&#x000a0;$733), prescriptions ($6,505&#x000a0;&#x000b1;&#x000a0;$372), and office-based visits ($4,716&#x000a0;&#x000b1;&#x000a0;$247). Annual expenditures for individuals with AF were higher than those without AF across all service categories. Trends in average unadjusted annual expenditure among individuals with AF over 2016 to 2021 are shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>. There was no increasing trend in expenditures across major expenditure categories.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Trends in Healthcare Expenditures Over Time for Individuals With AF</p><p>This bar graph shows average unadjusted annual total healthcare expenditures for individuals with AF by medical service category by year from 2016 to 2021 with <italic>P</italic> value for significance of trend. &#x02217;Denotes significant <italic>P</italic> value &#x0003c; 0.05.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0110">After adjusting for demographics, comorbidities, and survey year, the incremental average annual healthcare expenditure attributable to AF estimated from the 2-part regression model was $6,185 per person (95%&#x000a0;CI: $5,082-$7,288) (<xref rid="appsec1" ref-type="sec">Supplemental Appendix File 1</xref> for the 2-part model output). With a survey-weighted AF population of 3,564,763 as shown in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, this translates to an overall national healthcare expenditure of $22.1 billion per year.</p><p id="p0115">Incremental expenditures attributable to AF within subpopulations of individuals with the 7 other common chronic comorbidities of cancer, ASCVD, COPD, and HF are shown in <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>. From largest to smallest, the average marginal effects (95%&#x000a0;CI) of having AF in addition to cancer, COPD, T2DM, ASCVD, and HTN were $12,070 ($4,439-$19,700), $8,463 ($3,149-$13,778), $7,918 ($4,837-$10,999), $7,699 ($4,512-$10,886), and $6,665 ($5,084-$8,246), respectively. CKD and HF did not significantly impact AF expenditures with average marginal effects of $3,003 (&#x02212;$11,490 to $17,496) and $103 (&#x02212;$7,617 to $7,823), respectively (<xref rid="fig2" ref-type="fig">Central Illustration</xref>).<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Incremental Expenditures With AF Among Individuals With Other Common Chronic Comorbidities From Gamma Regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Subpopulation</th><th>Average Annual Sample Size, n<xref rid="tbl2fna" ref-type="table-fn">a</xref></th><th>Average Annual Weighted Population, N<xref rid="tbl2fna" ref-type="table-fn">a</xref></th><th>AF Prevalence</th><th>Incremental Expenditure With AF<break/>(95%&#x000a0;CI)</th></tr></thead><tbody><tr><td>Cancer<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="center">815</td><td align="center">8,706,310</td><td align="center">5.1%</td><td align="center">$12,070 ($4,439-$19,700)</td></tr><tr><td>COPD</td><td align="center">581</td><td align="center">5,705,185</td><td align="center">5.9%</td><td align="center">$8,463 ($3,149-$13,778)</td></tr><tr><td>T2DM</td><td align="center">2,630</td><td align="center">24,921,007</td><td align="center">2.8%</td><td align="center">$7,918 ($4,837-$10,999)</td></tr><tr><td>ASCVD</td><td align="center">1,389</td><td align="center">13,846,252</td><td align="center">8.9%</td><td align="center">$7,699 ($4,512-$10,886)</td></tr><tr><td>HTN</td><td align="center">6,101</td><td align="center">61,658,796</td><td align="center">3.6%</td><td align="center">$6,665 ($5,084-$8,246)</td></tr><tr><td>CKD</td><td align="center">124</td><td align="center">1,176,421</td><td align="center">6.5%</td><td align="center">$3,003 (&#x02212;$11,490 to $17,496)</td></tr><tr><td>HF</td><td align="center">176</td><td align="center">1,640,324</td><td align="center">15.3%</td><td align="center">$103 (&#x02212;$7,617 to $7,823)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p>Values are average marginal effect (95%&#x000a0;CI) of having AF from a gamma regression of individuals with a given comorbidity. Expenditures are reported in inflation-adjusted 2021 U.S. dollars.</p></fn><fn id="tspara0035"><p>AF&#x000a0;=&#x000a0;atrial fibrillation; ASCVD&#x000a0;=&#x000a0;atherosclerotic cardiovascular disease; CKD&#x000a0;=&#x000a0;chronic kidney disease; COPD&#x000a0;=&#x000a0;chronic obstructive pulmonary disease; HF&#x000a0;=&#x000a0;heart failure; HTN&#x000a0;=&#x000a0;hypertension; T2DM&#x000a0;=&#x000a0;type 2 diabetes mellitus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0025">Average annual population sizes are calculated by dividing each total population over 2016 to 2021 by 6&#x000a0;years and rounding up to the nearest whole integer.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0030">Due to the low sample size in subcategories, the insurance status variable was excluded from the gamma regression model for individuals with cancer to enable convergence.</p></fn></table-wrap-foot></table-wrap><fig id="fig2"><label>Central Illustration</label><caption><p>Annual and Incremental Expenditures With AF and&#x000a0;Comorbidities</p><p>The left graph shows the overall average unadjusted annual total healthcare expenditures, independent of AF, for AF and 7 common comorbidities of AF (CKD, HF, cancer, ASCVD, COPD, T2DM, and HF). The right graph shows incremental expenditures of AF among individuals with the 7 comorbidities. Made with BioRender.com. AF&#x000a0;=&#x000a0;atrial fibrillation; ASCVD&#x000a0;=&#x000a0;atherosclerotic cardiovascular disease; CKD&#x000a0;=&#x000a0;chronic kidney disease; COPD&#x000a0;=&#x000a0;chronic obstructive pulmonary disease; HF&#x000a0;=&#x000a0;heart failure; HTN&#x000a0;=&#x000a0;hypertension; T2DM&#x000a0;=&#x000a0;type 2 diabetes mellitus.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0120">Variables associated with increased total healthcare expenditure among individuals with AF are shown in <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>. Listing by OR magnitude, higher expenditures were associated with a diagnosis of cancer (OR: 1.84 [95%&#x000a0;CI: 1.39-2.43], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), modified CCI of&#x000a0;&#x02265;2 (OR: 1.83 [95%&#x000a0;CI: 1.24-2.69], <italic>P</italic>&#x000a0;=&#x000a0;0.002) and 1 (OR: 1.30 [95%&#x000a0;CI: 1.10-1.54], <italic>P</italic>&#x000a0;=&#x000a0;0.003), CKD (OR: 1.74 [95%&#x000a0;CI: 1.31-2.32], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), T2DM (OR: 1.45 [95%&#x000a0;CI 1.23-1.71], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), COPD (OR: 1.38 [95%&#x000a0;CI: 1.07-1.78], <italic>P</italic>&#x000a0;=&#x000a0;0.014), ASCVD (OR: 1.36 [95%&#x000a0;CI: 1.17-1.58], <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), poor (OR: 1.36 [95%&#x000a0;CI: 1.02-1.83], <italic>P</italic>&#x000a0;=&#x000a0;0.038), bachelor's degree (OR: 1.32 [95%&#x000a0;CI: 1.02-1.69], <italic>P</italic>&#x000a0;=&#x000a0;0.034), and later survey year (OR: 1.08 [95%&#x000a0;CI: 1.03-1.13], <italic>P</italic>&#x000a0;=&#x000a0;0.001).<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Factors Associated With Increased Total Healthcare Expenditures Among Individuals With AF From Gamma Regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>OR (95%&#x000a0;CI)</th><th><italic>P</italic> Value</th></tr></thead><tbody><tr><td>Age categories</td><td/><td/></tr><tr><td>&#x000a0;18-44&#x000a0;y (Ref)</td><td/><td/></tr><tr><td>&#x000a0;45-64&#x000a0;y</td><td align="center">0.59 (0.23-1.51)</td><td align="center">0.273</td></tr><tr><td>&#x000a0;65-84&#x000a0;y</td><td align="center">0.63 (0.16-2.44)</td><td align="center">0.506</td></tr><tr><td>&#x000a0;&#x02265;85&#x000a0;y</td><td align="center">0.72 (0.18-2.80)</td><td align="center">0.634</td></tr><tr><td>Sex</td><td/><td/></tr><tr><td>&#x000a0;Male (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Female</td><td align="center">0.96 (0.83-1.11)</td><td align="center">0.599</td></tr><tr><td>Survey year</td><td align="center">1.08 (1.03-1.13)</td><td align="center">0.001</td></tr><tr><td>Race/ethnicity</td><td/><td/></tr><tr><td>&#x000a0;Non-Hispanic White (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Hispanic</td><td align="center">0.97 (0.72-1.31)</td><td align="center">0.843</td></tr><tr><td>&#x000a0;Non-Hispanic Black</td><td align="center">0.81 (0.59-1.10)</td><td align="center">0.178</td></tr><tr><td>&#x000a0;Non-Hispanic Asian and other/mixed</td><td align="center">1.14 (0.66-1.95)</td><td align="center">0.639</td></tr><tr><td>Modified CCI</td><td/><td/></tr><tr><td>&#x000a0;0 (Ref)</td><td/><td/></tr><tr><td>&#x000a0;1</td><td align="center">1.30 (1.10-1.54)</td><td align="center">0.003</td></tr><tr><td>&#x000a0;&#x02265;2</td><td align="center">1.83 (1.24-2.69)</td><td align="center">0.002</td></tr><tr><td>Comorbidities</td><td/><td/></tr><tr><td>&#x000a0;Cancer</td><td align="center">1.84 (1.39-2.43)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x000a0;CKD</td><td align="center">1.74 (1.31-2.32)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x000a0;T2DM</td><td align="center">1.45 (1.23-1.71)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x000a0;COPD</td><td align="center">1.38 (1.07-1.78)</td><td align="center">0.014</td></tr><tr><td>&#x000a0;ASCVD</td><td align="center">1.36 (1.17-1.58)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x000a0;HF</td><td align="center">1.15 (0.93-1.42)</td><td align="center">0.200</td></tr><tr><td>&#x000a0;HTN</td><td align="center">1.06 (0.90-1.25)</td><td align="center">0.469</td></tr><tr><td>Education</td><td/><td/></tr><tr><td>&#x000a0;GED/HS grad (Ref)</td><td/><td/></tr><tr><td>&#x000a0;No degree</td><td align="center">0.76 (0.58-1.00)</td><td align="center">0.050</td></tr><tr><td>&#x000a0;Bachelor's</td><td align="center">1.32 (1.02-1.69)</td><td align="center">0.034</td></tr><tr><td>&#x000a0;Master/Doctorate</td><td align="center">1.23 (0.98-1.53)</td><td align="center">0.072</td></tr><tr><td>&#x000a0;Other degree</td><td align="center">0.83 (0.67-1.02)</td><td align="center">0.077</td></tr><tr><td>Marital status</td><td/><td/></tr><tr><td>&#x000a0;Married (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Widowed/divorced/separated</td><td align="center">1.12 (0.97-1.29)</td><td align="center">0.134</td></tr><tr><td>&#x000a0;Never married</td><td align="center">0.99 (0.73-1.36)</td><td align="center">0.973</td></tr><tr><td>Census region</td><td/><td/></tr><tr><td>&#x000a0;South (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Northeast</td><td align="center">1.15 (0.94-1.40)</td><td align="center">0.177</td></tr><tr><td>&#x000a0;Midwest</td><td align="center">1.18 (0.98-1.43)</td><td align="center">0.080</td></tr><tr><td>&#x000a0;West</td><td align="center">0.98 (0.76-1.25)</td><td align="center">0.845</td></tr><tr><td>Household income level</td><td/><td/></tr><tr><td>&#x000a0;High income (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Poor</td><td align="center">1.36 (1.02-1.83)</td><td align="center">0.038</td></tr><tr><td>&#x000a0;Near poor</td><td align="center">1.10 (0.84-1.45)</td><td align="center">0.481</td></tr><tr><td>&#x000a0;Low income</td><td align="center">0.99 (0.80-1.22)</td><td align="center">0.907</td></tr><tr><td>&#x000a0;Middle income</td><td align="center">1.13 (0.97-1.31)</td><td align="center">0.127</td></tr><tr><td>Insurance status</td><td/><td/></tr><tr><td>&#x000a0;Medicare (Ref)</td><td/><td/></tr><tr><td>&#x000a0;Private</td><td align="center">1.64 (0.62-4.35)</td><td align="center">0.323</td></tr><tr><td>&#x000a0;Other public</td><td align="center">0.98 (0.36-2.70)</td><td align="center">0.970</td></tr><tr><td>&#x000a0;Uninsured</td><td align="center">1.62 (0.98-2.69)</td><td align="center">0.062</td></tr></tbody></table><table-wrap-foot><fn><p>AF&#x000a0;=&#x000a0;atrial fibrillation; ASCVD&#x000a0;=&#x000a0;atherosclerotic cardiovascular disease; CCI&#x000a0;=&#x000a0;Charlson Comorbidity Index; CKD&#x000a0;=&#x000a0;chronic kidney disease; COPD&#x000a0;=&#x000a0;chronic obstructive pulmonary disease; GED&#x000a0;=&#x000a0;general education development; Grad&#x000a0;=&#x000a0;graduate; HF&#x000a0;=&#x000a0;heart failure; HS&#x000a0;=&#x000a0;high school; HTN&#x000a0;=&#x000a0;hypertension; Ref&#x000a0;=&#x000a0;reference; T2DM&#x000a0;=&#x000a0;type 2 diabetes mellitus.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0125">Individuals with AF had an average unadjusted annual total healthcare expenditure nearly 3 times that of individuals without AF. After adjustment for demographics, comorbidities, and survey year, AF was associated with an incremental annual expenditure of &#x0223c;$6,000 per person. Among individuals with AF, a higher comorbidity burden including cancer, CKD, T2DM, COPD, and ASCVD; lower income; bachelor's degree; and a later survey year were associated with higher expenditures. Furthermore, co-existent AF increased expenditures for individuals with chronic conditions such as cancer, COPD, T2DM, ASCVD, and HTN, but not for others like CKD and HF.</p><p id="p0130">Our findings build on prior studies focusing on healthcare expenditures in AF. In a systematic review of studies from 1990 to 2009, Wolowacz et&#x000a0;al<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> found the direct expenditures of AF across the 5 studies from the U.S. to vary from as low as $2,000 per patient-year to as high as $14,200. In another study, using a database of commercially insured patients from 2017 to 2020, Deshmukh et&#x000a0;al<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> found average total annual healthcare expenditure for patients with AF to be much higher at $63,031 ($27,896 more than those without AF). In addition, in a 1999 to 2002 privately insured database for 2 million enrollees, Wu et&#x000a0;al<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> reported that the excess annual direct expenditure of AF was $12,349 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), with individuals with AF having expenditures approximately 5 times higher than that for individuals without AF ($15,553 vs $3,204, respectively).</p><p id="p0135">In our study, we found average unadjusted annual healthcare expenditures for individuals with AF to be $25,241 per person per year, and after adjustment for demographics and comorbidities, the presence of AF was associated with an additional $6,185 incremental healthcare expenditure which translates to over $22&#x000a0;billion in healthcare expenditures annually attributable to AF. Thus, although AF is often considered to be a condition associated with other chronic conditions, our study shows that AF is also, in itself, a significant independent driver of expenditures. Healthcare expenditures for individuals with AF were noted to be in a similar range to the total expenditures for individuals with other common comorbidities such as cancer and ASCVD. With increasing prevalence of AF and healthcare expenditures comparable to other major chronic conditions, healthcare expenditures for AF deserve greater public attention and policy focus. Compared to the wide range of expenditures reported by prior studies, our estimates are likely more accurate and representative of current expenditures among individuals with AF in the U.S. as the MEPS is a national standard in assessing expenditures of medical conditions in the population, measuring both direct payments for healthcare services and out-of-pocket payments. In addition, MEPS includes participants across all insurance statuses.</p><p id="p0140">Inpatient (hospitalization) expenditures were the largest contributor to expenditures among individuals with AF&#x02014;consistent with prior studies<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>&#x02014;and accounted for nearly a third of the total expenditure. Hospitalization expenditures, however, did not change significantly over time. Hospitalizations among individuals with AF could be related to complications from AF such as stroke, thromboembolism, or anticoagulant-related issues or related to the other co-existent comorbidities.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> On the other hand, the use of ablation procedures and cardioversions to maintain sinus rhythm and left atrial appendage for stroke prevention may also be a contributor to hospitalizations. Prior studies show that the use of catheter ablation strategies for AF patients increased by 15% per year.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> As studies have suggested that ablation may reduce downstream costs compared to medical therapy,<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref> it is possible that over time, hospitalization expenditures among individuals with AF may decrease. The strength of the ongoing survey design of MEPS is that it allows periodic reassessment of hospitalization costs to monitor this trend.</p><p id="p0145">Prescription expenditures were the second largest contributor to AF expenditures. A recent innovation in AF management has been the emergence of DOACs which have had significantly increased use over the past decade.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Besides DOACs, antiarrhythmic drug usage also contributes to prescription expenditures among individuals with AF.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> However, despite the trend in increased DOAC usage, our study showed no significant change in prescription expenditures. With DOACs potentially becoming available in a generic form in the future, prescription expenditures may decrease over the next decade. Furthermore, increasing the use of DOACs over vitamin K antagonists may reduce expenditures in other categories such as outpatient expenditures and hospitalizations from lesser monitoring needs, benefits for elderly or frail patients, and lower incidence of bleeding events and AF-related stroke, which can in turn reduce total expenditure.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref></p><p id="p0150">Among individuals with AF, there were no significant changes in average unadjusted annual total expenditure during the 2016 to 2021 study period across major categories of expenditures. The only statistically significant expenditure category was the "other" category including dental and vision expenditures, which grew by 48.9%. Longer time periods are needed to analyze how changes in AF epidemiology and management affect expenditures across categories.</p><p id="p0155">Interestingly, both having a bachelor's degree and being poor (having a household income less than or equal to FPL) were associated with increased total healthcare expenditure among individuals with AF. While low educational attainment has been associated with increased risk of hospitalization<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> and likely related expenditures, it is possible that individuals with higher education attainment may have greater health literacy and awareness of available treatments such as catheter ablation and DOACs, leading to increased healthcare utilization and expenditures. Conversely, patients with low socioeconomic status have been found to have limited access to outpatient care<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> and are less likely to visit cardiologists or receive rhythm control interventions after AF diagnosis, particularly catheter ablation.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> While the lack of these preventative measures may initially reduce cost, in the long run, they have been shown to increase rates of emergency visits,<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> in-hospital mortality,<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> adverse outcomes,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> and expenditures as found in our study. Furthermore, race is intertwined with education and income, and while our study showed no differences in expenditures by race or ethnicity, 89% of our population of AF patients was White, limiting in-depth analyses. Unfortunately, most AF studies have also included predominantly White populations,<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> and data show that racial and ethnic minorities have underused catheter ablation.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> More studies are essential to identify and meet the needs of vulnerable populations with AF, including those with a low socioeconomic status and minorities.</p><p id="p0160">A novel insight from our study is that co-existent AF increases health expenditures for individuals with some chronic conditions but does not change expenditures for others. For instance, incremental expenditures attributable to AF were greatest in cancer cases ($12,070), on the other hand, AF did not change expenditures for individuals with CKD and HF. It is possible that for some conditions, AF may signify more disease severity and lead to additional treatments increasing expenditures, while for other conditions, there may be shared treatments between the 2 conditions. Understanding the reasons for this finding requires further study of how AF changes expenditures for various chronic conditions by individual spending categories.</p><p id="p0165">In the coming years, the total expenditures for individuals with AF may continue to increase. Newer classes of AF medications and the increasing use of procedural and device therapies may be drivers of expenditures. On the other hand, with&#x000a0;more efficacious treatments and monitoring, there may be reductions in other expenditures, such&#x000a0;as decreased hospitalizations. The ongoing survey and consistent methodology are strengths of using the MEPS database and allow for close monitoring of patterns of change in expenditures over time.</p><sec id="sec3.1"><title>Study limitations</title><p id="p0170">Our study has several limitations. First, due to high rates of comorbidities among individuals with AF, there may be residual confounding after multivariable adjustment making it harder to assess independent effects of AF on expenditure. Second, our study overlapped with the COVID-19 pandemic from 2019 to 2021. Thus, there may be short-term changes in expenditure patterns that warrant reassessment in coming years. Third, because the MEPS database lacks information on procedures, we are unable to report expenditures of AF-associated procedures such as ablation and left atrial appendage closure and how they relate to expenditures as they are captured as part of inpatient expenditures. MEPS also lacks participant representation from institutionalized individuals including nursing home residents.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> In addition, our study does not account for indirect expenditures incurred by individuals, such as income lost due to reduced productivity and caregiver expenses. Thus, actual expenditures incurred by individuals with AF may be higher than the direct expenditures reported in the study. An additional limitation is that the self-reported nature of MEPS data can lead to underreporting of expenditures. For personal healthcare spending estimates, MEPS data have been reported to be lower than National Health Expenditure Accounts data from the Centers for Medicare and Medicaid Services. Specifically, MEPS reports $240.3 billion or 17.6% less expenditures than the adjusted National Health Expenditure Accounts total expenditures.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> These different may be caused by different factors including sampling bias, nonresponse bias, attrition, and other measurement errors.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></p></sec></sec><sec id="sec4"><title>Conclusions</title><p id="p0175">Individuals with AF have high healthcare expenditures, and expenditures attributable to AF amount to over $22 billion in U.S. spending every year. Furthermore, the co-existence of AF among individuals with comorbidities like cancer, CKD, T2DM, COPD, and ASCVD significantly increases their healthcare expenditures. Given these high expenditures and increasing prevalence, AF warrants increased focus from healthcare policy makers. Continued advancements in AF management and the resulting improvements in cardiovascular health could lead to reductions in long-term healthcare expenditures. Thus, there is a need to periodically reassess expenditures.<boxed-text id="dtbox1"><label>Perspectives</label><p id="p0180"><bold>COMPETENCY IN SYSTEMS-BASED PRACTICE 1:</bold> Individuals with AF incur $25,451 of healthcare expenditures per year, and expenditures are increasing over time. The incremental expenditure per year attributable to AF is $6,185 after multivariable adjustment. This translates to an overall national healthcare expenditure of $22.1 billion per year. AF increases expenditures further among individuals with other chronic diseases.</p><p id="p0185"><bold>COMPETENCY IN SYSTEMS-BASED PRACTICE 2:</bold> Individuals with AF with more comorbidities including cancer, CKD, T2DM, COPD, and ASCVD; poor income level; a bachelor's degree; or later survey year had higher annual healthcare expenditures after multivariable adjustment.</p><p id="p0190"><bold>COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS:</bold> Given high expenditures, AF needs increased focus of policy makers. With increased detection and changes in treatment of AF, expenditures need continual assessments.</p><p id="p0195"><bold>TRANSLATIONAL OUTLOOK:</bold> This study, which uses an all-payer nationally representative annual cross-sectional survey of medical expenditures of the United States civilian noninstitutionalized population, found that: 1) individuals with AF had average unadjusted annual total healthcare expenditures nearly 3 times that of individuals without AF, with total expenditures increasing by 11.1% from 2016 to 2021; 2) after a multivariable adjustment, the incremental annual expenditure was approximately $6,000 per person with AF, translating to over $22 billion in healthcare expenditures annually; and 3) among individuals with AF, a higher comorbidity burden including cancer, CKD, T2DM, COPD, and ASCVD; poor income level; bachelor's degree; and later survey year were associated with higher expenditures. With an aging U.S. population and new screening and management methods, further studies are needed to reassess trends in healthcare expenditures in AF over time.</p></boxed-text></p></sec><sec sec-type="COI-statement" id="coi0010"><title>Funding support and author disclosures</title><p id="p0205">Dr See has received support from the <funding-source id="gs4">Yale School of Medicine</funding-source> 2023 Fellowship for Medical Student Research. Dr Murugiah has received support from the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute of the National Institutes of Health</institution></institution-wrap></funding-source> (under award K08HL157727). Dr Nanna has received research support from the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005485</institution-id><institution>American College of Cardiology</institution></institution-wrap></funding-source> (George F and Ann Harris Bellows Foundation), the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006093</institution-id><institution>Patient-Centered Outcomes Research Institute</institution></institution-wrap></funding-source>, the <funding-source id="gs8">Yale Claude D. Pepper Older Americans Independence Center</funding-source> (P30AG021342), and the <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000049</institution-id><institution>National Institute on Aging/National Institutes of Health</institution></institution-wrap></funding-source> (GEMSSTAR award: R03AG074067); and has received current research support from the <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005485</institution-id><institution>American College of Cardiology Foundation</institution></institution-wrap></funding-source> supported by the <funding-source id="gs12">George F. and Ann Harris Bellows Foundation</funding-source>, the <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006093</institution-id><institution>Patient-Centered Outcomes Research Institute</institution></institution-wrap></funding-source> (PCORI), the <funding-source id="gs15">Yale Claude D. Pepper Older Americans Independence Center</funding-source> (P30AG021342), and the <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source> from K76AG088428; honoraria and consulting fees from Heartflow Inc, Novo Nordisk, and Merck. Dr Freeman has received research support from the <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000050</institution-id><institution>National Institutes of Health National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source> and the <funding-source id="gs18"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005485</institution-id><institution>American College of Cardiology</institution></institution-wrap></funding-source> National Cardiovascular Data Registry and advisory board/consulting with Boston Scientific, Medtronic, Abbott, Biosense Webster, and PaceMate. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>January</surname><given-names>C.T.</given-names></name><name><surname>Wann</surname><given-names>L.S.</given-names></name><name><surname>Alpert</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>64</volume><year>2014</year><fpage>e1</fpage><lpage>e76</lpage><pub-id pub-id-type="pmid">24685669</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Colilla</surname><given-names>S.</given-names></name><name><surname>Crow</surname><given-names>A.</given-names></name><name><surname>Petkun</surname><given-names>W.</given-names></name><name><surname>Singer</surname><given-names>D.E.</given-names></name><name><surname>Simon</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population</article-title><source>Am J Cardiol</source><volume>112</volume><year>2013</year><fpage>1142</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">23831166</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Kornej</surname><given-names>J.</given-names></name><name><surname>B&#x000f6;rschel</surname><given-names>C.S.</given-names></name><name><surname>Benjamin</surname><given-names>E.J.</given-names></name><name><surname>Schnabel</surname><given-names>R.B.</given-names></name></person-group><article-title>Epidemiology of atrial fibrillation in the 21st century</article-title><source>Circ Res</source><volume>127</volume><year>2020</year><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">32716709</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>E.J.</given-names></name><name><surname>Muntner</surname><given-names>P.</given-names></name><name><surname>Alonso</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2019 update: a report from the American Heart Association</article-title><source>Circulation</source><volume>139</volume><year>2019</year><fpage>e56</fpage><lpage>e528</lpage><pub-id pub-id-type="pmid">30700139</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.H.</given-names></name><name><surname>Johnston</surname><given-names>S.S.</given-names></name><name><surname>Chu</surname><given-names>B.C.</given-names></name><name><surname>Dalal</surname><given-names>M.R.</given-names></name><name><surname>Schulman</surname><given-names>K.L.</given-names></name></person-group><article-title>Estimation of total incremental health care costs in patients with atrial fibrillation in the United States</article-title><source>Circ Cardiovasc Qual Outcomes</source><volume>4</volume><year>2011</year><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">21540439</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Burdett</surname><given-names>P.</given-names></name><name><surname>Lip</surname><given-names>G.Y.H.</given-names></name></person-group><article-title>Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs</article-title><source>Eur Heart J Qual Care Clin Outcomes</source><volume>8</volume><year>2022</year><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">33346822</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>E.J.</given-names></name><name><surname>Wolf</surname><given-names>P.A.</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>R.B.</given-names></name><name><surname>Silbershatz</surname><given-names>H.</given-names></name><name><surname>Kannel</surname><given-names>W.B.</given-names></name><name><surname>Levy</surname><given-names>D.</given-names></name></person-group><article-title>Impact of atrial fibrillation on the risk of death</article-title><source>Circulation</source><volume>98</volume><year>1998</year><fpage>946</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">9737513</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>A.M.</given-names></name><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Gersh</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Multimorbidity and the risk of hospitalization and death in atrial fibrillation: a population-based study</article-title><source>Am Heart J</source><volume>185</volume><year>2017</year><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">28267478</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Jani</surname><given-names>B.D.</given-names></name><name><surname>Nicholl</surname><given-names>B.I.</given-names></name><name><surname>McQueenie</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort</article-title><source>EP Europace</source><volume>20</volume><year>2017</year><fpage>f329</fpage><lpage>f336</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.W.</given-names></name><name><surname>Cohen</surname><given-names>S.B.</given-names></name><name><surname>Banthin</surname><given-names>J.S.</given-names></name></person-group><article-title>The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice</article-title><source>Med Care</source><volume>47</volume><year>2009</year><fpage>S44</fpage><lpage>S50</lpage><pub-id pub-id-type="pmid">19536015</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="other" id="sref11"><article-title>MEPS-HC response rates by panel display page in printer friendly format printer-friendly. Agency for Healthcare Research And Quality</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/survey_comp/hc_response_rate.jsp" id="intref0015">https://meps.ahrq.gov/survey_comp/hc_response_rate.jsp</ext-link></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="other" id="sref12"><person-group person-group-type="author"><name><surname>Survey</surname><given-names>M.E.P.</given-names></name></person-group><article-title>Question: Does the DUPERSID variable uniquely identify a person in the MEPS survey?: Agency for Healthcare Research and Quality</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/about_meps/faq_answers.jsp?FAQID=127&#x00026;ChooseCategory=5&#x00026;keyword=" id="intref0020">https://meps.ahrq.gov/about_meps/faq_answers.jsp?FAQID=127&#x00026;ChooseCategory=5&#x00026;keyword=</ext-link></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="other" id="sref13"><article-title>MEPS HC-231: 2021 medical conditions. Agency for Healthcare Research and Quality</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data/pufs/h231/h231doc.pdf" id="intref0025">https://meps.ahrq.gov/data_stats/download_data/pufs/h231/h231doc.pdf</ext-link></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="other" id="sref14"><article-title>MEPS HC-192 2016 full year consolidated data file. Agency for Healthcare Research and Quality, August 2018</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data/pufs/h192/h192doc.pdf" id="intref0030">https://meps.ahrq.gov/data_stats/download_data/pufs/h192/h192doc.pdf</ext-link></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="other" id="sref15"><article-title>MEPS HC-209 2018 full year consolidated data file. Agency for Healthcare Research and Quality, August 2020</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf" id="intref0035">https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf</ext-link></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="other" id="sref16"><article-title>MEPS HC-231 2021 medical conditions. Agency for Healthcare Research and Quality, August 2023</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf" id="intref0040">https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf</ext-link></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="other" id="sref17"><article-title>MEPS HC-036: 1996-2015 pooled linkage variance estimation file - 4.0 adjustment of analytic weight variable. Agency for Healthcare Research and Quality (AHRQ), September 2017</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml#40Other" id="intref0045">https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml#40Other</ext-link></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="other" id="sref18"><article-title>MEPS-HC Summary Data Tables&#x000a0;Technical Notes. Agency for Healthcare Research and Quality</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/survey_comp/hc_technical_notes.shtml" id="intref0025a">https://meps.ahrq.gov/survey_comp/hc_technical_notes.shtml</ext-link></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="other" id="sref19"><person-group person-group-type="author"><name><surname>Stagg</surname><given-names>V.</given-names></name></person-group><article-title>Charlson comorbidity index macro. University of Calgary</article-title><ext-link ext-link-type="uri" xlink:href="http://fmwww.bc.edu/RePEc/bocode/c/charlson.html" id="intref0050">http://fmwww.bc.edu/RePEc/bocode/c/charlson.html</ext-link></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="other" id="sref20"><person-group person-group-type="author"><name><surname>Machlin</surname><given-names>S.R.</given-names></name><name><surname>Dougherty</surname><given-names>D.D.</given-names></name></person-group><article-title>Methodology Report #19: Overview of Methodology for Imputing Missing Expenditure Data in the Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality</article-title><ext-link ext-link-type="uri" xlink:href="https://www.meps.ahrq.gov/data_files/publications/mr19/mr19.shtml" id="intref0050a">https://www.meps.ahrq.gov/data_files/publications/mr19/mr19.shtml</ext-link></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="other" id="sref21"><person-group person-group-type="author"><name><surname>William</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>S.M.</given-names></name></person-group><article-title>Examination of Skewed Health Expenditure Data from the Medical Expenditure Panel Survey (MEPS). Agency for Healthcare Research and Quality Working Paper No. 04002,&#x000a0;2004</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/data_files/publications/workingpapers/wp_04002.pdf" id="intref0050g">https://meps.ahrq.gov/data_files/publications/workingpapers/wp_04002.pdf</ext-link></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Morey</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Estimated health care utilization and expenditures in individuals with heart failure from the medical expenditure panel survey</article-title><source>Circ Heart Fail</source><volume>14</volume><year>2021</year><object-id pub-id-type="publisher-id">e007763</object-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Bhatnagar</surname><given-names>R.</given-names></name><name><surname>Fonarow</surname><given-names>G.C.</given-names></name><name><surname>Heidenreich</surname><given-names>P.A.</given-names></name><name><surname>Ziaeian</surname><given-names>B.</given-names></name></person-group><article-title>Expenditure on heart failure in the United States: the medical expenditure panel survey 2009-2018</article-title><source>JACC Heart Fail</source><volume>10</volume><year>2022</year><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">35902161</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="other" id="sref24"><article-title>TABLE&#x000a0;1. ICD-9-CM and ICD-10 Coding Algorithms for Charlson Comorbidities. Manitoba Centre for Health Policy: University of Manitoba</article-title><ext-link ext-link-type="uri" xlink:href="http://mchp-appserv.cpe.umanitoba.ca/concept/Charlson%20Comorbidities%20-%20Coding%20Algorithms%20for%20ICD-9-CM%20and%20ICD-10.pdf" id="intref0027a">http://mchp-appserv.cpe.umanitoba.ca/concept/Charlson%20Comorbidities%20-%20Coding%20Algorithms%20for%20ICD-9-CM%20and%20ICD-10.pdf</ext-link></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Wolowacz</surname><given-names>S.E.</given-names></name><name><surname>Samuel</surname><given-names>M.</given-names></name><name><surname>Brennan</surname><given-names>V.K.</given-names></name><name><surname>Jasso-Mosqueda</surname><given-names>J.-G.</given-names></name><name><surname>Van Gelder</surname><given-names>I.C.</given-names></name></person-group><article-title>The cost of illness of atrial fibrillation: a systematic review of the recent literature</article-title><source>EP Europace</source><volume>13</volume><year>2011</year><fpage>1375</fpage><lpage>1385</lpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>A.</given-names></name><name><surname>Iglesias</surname><given-names>M.</given-names></name><name><surname>Khanna</surname><given-names>R.</given-names></name><name><surname>Beaulieu</surname><given-names>T.</given-names></name></person-group><article-title>Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation</article-title><source>Heart Rhythm O2</source><volume>3</volume><year>2022</year><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">36340482</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>E.Q.</given-names></name><name><surname>Birnbaum</surname><given-names>H.G.</given-names></name><name><surname>Mareva</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Economic burden and co-morbidities of atrial fibrillation in a privately insured population</article-title><source>Curr Med Res Opin</source><volume>21</volume><year>2005</year><fpage>1693</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">16238910</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="book" id="sref28"><person-group person-group-type="author"><name><surname>Nesheiwat</surname><given-names>Z.</given-names></name><name><surname>Goyal</surname><given-names>A.</given-names></name><name><surname>Jagtap</surname><given-names>M.</given-names></name></person-group><part-title>Atrial fibrillation</part-title><source>StatPearls</source><year>2023</year><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="other" id="sref29"><person-group person-group-type="author"><name><surname>Thording</surname><given-names>L.</given-names></name></person-group><article-title>EP single-use device reprocessing by the numbers. Innovate Health</article-title><ext-link ext-link-type="uri" xlink:href="https://innovative-health.com/wp-content/uploads/2014/10/EP-Single-Use-Device-Reprocessing-by-the-Numbers_ART0139-Rev.-1.pdf" id="intref0050x">https://innovative-health.com/wp-content/uploads/2014/10/EP-Single-Use-Device-Reprocessing-by-the-Numbers_ART0139-Rev.-1.pdf</ext-link></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>D.S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cowper</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Cost-Effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial</article-title><source>Circulation</source><volume>146</volume><year>2022</year><fpage>535</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">35726631</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Dhande</surname><given-names>M.</given-names></name><name><surname>Barakat</surname><given-names>A.</given-names></name><name><surname>Canterbury</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cardiovascular hospitalizations and resource use following atrial fibrillation ablation</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">e028609</object-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Field</surname><given-names>M.E.</given-names></name><name><surname>Gold</surname><given-names>M.R.</given-names></name><name><surname>Rahman</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation</article-title><source>J&#x000a0;Cardiovasc Electrophysiol</source><volume>31</volume><year>2020</year><fpage>3166</fpage><lpage>3175</lpage><pub-id pub-id-type="pmid">33022815</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Navar</surname><given-names>A.M.</given-names></name><name><surname>Kolkailah</surname><given-names>A.A.</given-names></name><name><surname>Overton</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>11</volume><year>2022</year><object-id pub-id-type="publisher-id">e026723</object-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Markman</surname><given-names>T.M.</given-names></name><name><surname>Geng</surname><given-names>Z.</given-names></name><name><surname>Epstein</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Trends in antiarrhythmic drug use among patients in the United States between 2004 and 2016</article-title><source>Circulation</source><volume>141</volume><year>2020</year><fpage>937</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">32176541</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Pyyk&#x000f6;nen</surname><given-names>M.</given-names></name><name><surname>Linna</surname><given-names>M.</given-names></name><name><surname>Tykkyl&#x000e4;inen</surname><given-names>M.</given-names></name><name><surname>Delmelle</surname><given-names>E.</given-names></name><name><surname>Laatikainen</surname><given-names>T.</given-names></name></person-group><article-title>Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin</article-title><source>BMC Health Serv Res</source><volume>21</volume><year>2021</year><fpage>1299</fpage><pub-id pub-id-type="pmid">34856979</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-L&#x000f3;pez</surname><given-names>J.A.</given-names></name><name><surname>Sterne</surname><given-names>J.A.C.</given-names></name><name><surname>Thom</surname><given-names>H.H.Z.</given-names></name><etal/></person-group><article-title>Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis</article-title><source>BMJ</source><volume>359</volume><year>2017</year><object-id pub-id-type="publisher-id">j5058</object-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Ruff</surname><given-names>C.T.</given-names></name><name><surname>Giugliano</surname><given-names>R.P.</given-names></name><name><surname>Braunwald</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials</article-title><source>Lancet</source><volume>383</volume><year>2014</year><fpage>955</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">24315724</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>A.</given-names></name><name><surname>Gale</surname><given-names>C.P.</given-names></name><name><surname>Ashton</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation</article-title><source>Heart</source><volume>107</volume><year>2021</year><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">33122302</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Tertulien</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Althouse</surname><given-names>A.D.</given-names></name><name><surname>Essien</surname><given-names>U.R.</given-names></name><name><surname>Johnson</surname><given-names>A.</given-names></name><name><surname>Magnani</surname><given-names>J.W.</given-names></name></person-group><article-title>Association of income and educational attainment in hospitalization events in atrial fibrillation</article-title><source>Am J Prev Cardiol</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">100201</object-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Hagengaard</surname><given-names>L.</given-names></name><name><surname>Andersen</surname><given-names>M.P.</given-names></name><name><surname>Polcwiartek</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Socioeconomic differences in outcomes after hospital admission for atrial fibrillation or flutter</article-title><source>Eur Heart J Qual Care Clin Outcomes</source><volume>7</volume><year>2021</year><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">31560375</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Abdel-Qadir</surname><given-names>H.</given-names></name><name><surname>Akioyamen</surname><given-names>L.E.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association of neighborhood-level material deprivation with atrial fibrillation care in a single-payer health care system: a population-based cohort study</article-title><source>Circulation</source><volume>146</volume><year>2022</year><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">35678171</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Eberly</surname><given-names>L.A.</given-names></name><name><surname>Garg</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Racial/ethnic and socioeconomic disparities in management of incident paroxysmal atrial fibrillation</article-title><source>JAMA Netw Open</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">e210247</object-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>S.R.</given-names></name><name><surname>Choi</surname><given-names>E.K.</given-names></name><name><surname>Han</surname><given-names>K.D.</given-names></name><name><surname>Oh</surname><given-names>S.</given-names></name><name><surname>Lip</surname><given-names>G.Y.H.</given-names></name></person-group><article-title>Impact of socioeconomic status on emergency department visits in patients with atrial fibrillation: a nationwide population-based cohort study</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>11</volume><year>2022</year><object-id pub-id-type="publisher-id">e027192</object-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Kotta</surname><given-names>P.A.</given-names></name><name><surname>Nambi</surname><given-names>V.</given-names></name><name><surname>Misra</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association between neighborhood household income and inpatient atrial fibrillation outcomes</article-title><source>Heart Rhythm</source><volume>21</volume><year>2024</year><fpage>993</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">38382688</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>LaRosa</surname><given-names>A.R.</given-names></name><name><surname>Claxton</surname><given-names>J.</given-names></name><name><surname>O'Neal</surname><given-names>W.T.</given-names></name><etal/></person-group><article-title>Association of household income and adverse outcomes in patients with atrial fibrillation</article-title><source>Heart</source><volume>106</volume><year>2020</year><fpage>1679</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">32144188</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>K.L.</given-names></name><name><surname>Al-Khalidi</surname><given-names>H.R.</given-names></name><name><surname>Silverstein</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Ablation versus drug therapy for atrial fibrillation in racial and ethnic minorities</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>78</volume><year>2021</year><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">34238436</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="other" id="sref47"><article-title>MEPS sample persons in-scope for part of the year: identification and analytic considerations. Medical Expenditure Panel Survey, April 2005</article-title><ext-link ext-link-type="uri" xlink:href="https://meps.ahrq.gov/about_meps/hc_sample.shtml" id="intref0055">https://meps.ahrq.gov/about_meps/hc_sample.shtml</ext-link></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>D.</given-names></name><name><surname>Cowan</surname><given-names>C.</given-names></name><name><surname>Selden</surname><given-names>T.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Catlin</surname><given-names>A.</given-names></name><name><surname>Heffler</surname><given-names>S.</given-names></name></person-group><article-title>Reconciling medical expenditure estimates from the MEPS and NHEA, 2007</article-title><source>Medicare Medicaid Res Rev</source><volume>2</volume><year>2012</year><object-id pub-id-type="publisher-id">mmrr.002.04.a09</object-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Aizcorbe</surname><given-names>A.</given-names></name><name><surname>Liebman</surname><given-names>E.</given-names></name><name><surname>Pack</surname><given-names>S.</given-names></name><name><surname>Cutler</surname><given-names>D.M.</given-names></name><name><surname>Chernew</surname><given-names>M.E.</given-names></name><name><surname>Rosen</surname><given-names>A.B.</given-names></name></person-group><article-title>Measuring health care costs of individuals with employer-sponsored health insurance in the U.S.: a comparison of&#x000a0;survey and claims data</article-title><source>Stat J IAOS</source><volume>28</volume><year>2012</year><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">26146526</pub-id>
</element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0215">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary data</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0210">The authors thank the Yale StatLab student consultant team for their statistical advice.</p></ack><fn-group><fn id="d36e1308"><p id="ntpara0015aa">The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors&#x02019; institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the <ext-link ext-link-type="uri" xlink:href="https://www.jacc.org/author-center" id="interref1">Author Center</ext-link>.</p></fn><fn id="appsec2"><p>Appendix</p><p id="p0220">For a supplemental table and file, please see the online version of this paper.</p></fn></fn-group></back></article>